A method of predicting the resistance of a biological sample to the damaging effects of ionizing radiation applied to the biological sample is described, where the method includes measuring by electron paramagnetic resonance (EPR) spectroscopy the amount of divalent manganese (Mn.sup.2+) present in the biological sample; and then determining the resistance of the biological sample to the ionizing radiation based on the measured amount of the divalent manganese.

A method of predicting the resistance of a biological sample to the damaging effects of ionizing radiation applied to the biological sample is described, where the method includes measuring by electron paramagnetic resonance (EPR) spectroscopy the amount of divalent manganese (Mn.sup.2+) present in the biological sample; and then determining the resistance of the biological sample to the ionizing radiation based on the measured amount of the divalent manganese.

This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (V): ##STR00001##
wherein R.sub.1 and R.sub.2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.

Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (V): ##STR00001##
wherein R.sub.1 and R.sub.2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.

Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.

Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an allograft antigen and a redox motif such as C-(X)2-[CST] (SEQ ID NO: 18) or [CST]-(X)2-C(SEQ ID NO: 19) in the prevention and/or treatment of allograft rejection and in the manufacture of medicaments therefore.

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an allograft antigen and a redox motif such as C-(X)2-[CST] (SEQ ID NO: 18) or [CST]-(X)2-C(SEQ ID NO: 19) in the prevention and/or treatment of allograft rejection and in the manufacture of medicaments therefore.